| Literature DB >> 36226070 |
Martina Moglioni1,2, Aafke Christine Kraan1, Guido Baroni3,4, Giuseppe Battistoni5, Nicola Belcari1,2, Andrea Berti1,2,6, Pietro Carra1,2, Piergiorgio Cerello7, Mario Ciocca3, Angelica De Gregorio8,9, Micol De Simoni8,9, Damiano Del Sarto1,2, Marco Donetti3, Yunsheng Dong5,10, Alessia Embriaco11, Maria Evelina Fantacci1,2, Veronica Ferrero7, Elisa Fiorina3,7, Marta Fischetti9,12, Gaia Franciosini8,9, Giuseppe Giraudo7, Francesco Laruina1,2, Davide Maestri3, Marco Magi12, Giuseppe Magro3, Etesam Malekzadeh3,13, Michela Marafini9,14, Ilaria Mattei5, Enrico Mazzoni1, Paolo Mereu7, Alfredo Mirandola3, Matteo Morrocchi1,2, Silvia Muraro5, Ester Orlandi3, Vincenzo Patera9,12, Francesco Pennazio7, Marco Pullia3, Alessandra Retico1, Angelo Rivetti7, Manuel Dionisio Da Rocha Rolo7, Valeria Rosso1,2, Alessio Sarti9,12, Angelo Schiavi9,12, Adalberto Sciubba12,15, Giancarlo Sportelli1,2, Sara Tampellini3, Marco Toppi12,15, Giacomo Traini9,14, Antonio Trigilio8,9, Serena Marta Valle5, Francesca Valvo3, Barbara Vischioni3, Viviana Vitolo3, Richard Wheadon7, Maria Giuseppina Bisogni1,2.
Abstract
Morphological changes that may arise through a treatment course are probably one of the most significant sources of range uncertainty in proton therapy. Non-invasive in-vivo treatment monitoring is useful to increase treatment quality. The INSIDE in-beam Positron Emission Tomography (PET) scanner performs in-vivo range monitoring in proton and carbon therapy treatments at the National Center of Oncological Hadrontherapy (CNAO). It is currently in a clinical trial (ID: NCT03662373) and has acquired in-beam PET data during the treatment of various patients. In this work we analyze the in-beam PET (IB-PET) data of eight patients treated with proton therapy at CNAO. The goal of the analysis is twofold. First, we assess the level of experimental fluctuations in inter-fractional range differences (sensitivity) of the INSIDE PET system by studying patients without morphological changes. Second, we use the obtained results to see whether we can observe anomalously large range variations in patients where morphological changes have occurred. The sensitivity of the INSIDE IB-PET scanner was quantified as the standard deviation of the range difference distributions observed for six patients that did not show morphological changes. Inter-fractional range variations with respect to a reference distribution were estimated using the Most-Likely-Shift (MLS) method. To establish the efficacy of this method, we made a comparison with the Beam's Eye View (BEV) method. For patients showing no morphological changes in the control CT the average range variation standard deviation was found to be 2.5 mm with the MLS method and 2.3 mm with the BEV method. On the other hand, for patients where some small anatomical changes occurred, we found larger standard deviation values. In these patients we evaluated where anomalous range differences were found and compared them with the CT. We found that the identified regions were mostly in agreement with the morphological changes seen in the CT scan.Entities:
Keywords: clinical trial; in-beam PET imaging; in-vivo treatment verification; inter-fractional range differences; morphological changes; proton therapy
Year: 2022 PMID: 36226070 PMCID: PMC9549776 DOI: 10.3389/fonc.2022.929949
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Reference frames. (A) Sketch of the INSIDE setup and reference frame. (B) Example of the three orthogonal projections of a reconstructed PET image for patient 002P (see 2.3). (C) The same reconstructed PET image in the CT reference frame. In (B, C) the beam axis is indicated with the red arrow. (D) The color-scale of the PET images.
Patients treated with protons analyzed in this work, with patient ID, pathology, number of fields, number of fractions delivered, number of fractions monitored, the control CT outcome, as evaluated by the radiation oncologist, and the monitored treatment angle.
| Patient | Pathology |
|
|
| Control CT | Monitored |
|---|---|---|---|---|---|---|
| ID | outcome | angle [°IEC] | ||||
| 002P | Meningioma | 2 | 30 | 12 | unchanged | 240 |
| 003P | Meningioma | 2 | 27 | 9 | unchanged | 235 |
| 004P | Meningioma | 2 | 31 | 8 | unchanged | 245 |
| 005P | Chordoma | 2 | 27 | 10 | unchanged | 5 |
| 006P | Adenoid Cystic Carcinoma | 2 | 35 | 10 | changed | 175 |
| 007P | Adenoid Cystic Carcinoma | 3 | 33 | 5 | changed | 270 |
| 008P | Adenoid Cystic Carcinoma | 3 | 33 | 11 | unchanged | 0 |
| 009P | Chondrosarcoma | 3 | 27 | 10 | unchanged | 0 |
Figure 2Planning CT (upper row) and control CT (lower row) for patient 006P. (A) Axial, (B) sagittal and (C) coronal views for the planning CT, and (D) Axial, (E) sagittal and (F) coronal views for the control CT. The morphological change is highlighted with a red arrow. Also, the CTV (Clinical Target Volume) area is highlighted with a green line.
Figure 3Planning CT (upper row) and control CT (lower row) for patient 007P. (A) Axial, (B) sagittal and (C) coronal views for the planning CT, and (D) Axial, (E) sagittal and (F) coronal views for the control CT. The morphological change is highlighted with a red arrows and the CTV (Clinical Target Volume) area is highlighted with a green line.
Figure 4Coronal views of the planning CT of patient 004P: reconstructed PET images corresponding to the monitored fractions 1 and 3. The left and right image had different dose delivery and acquisition times, resulting in different activities. Fraction 3 had to be excluded because of the larger activity compared to the other fractions.
Figure 5Examples of the distributions of inter-fractional range differences δR(x,y) of various fractions with respect to the reference (M) in patient 005P for the MLS method (A) and the BEV method (B). The dashed lines represent the 95% confidence interval tailored for, the MLS (5.0 mm) and the BEV method (4.6 mm) as 2<σ>.
Figure 6Inter-fractional standard deviation of the range difference distribution as obtained with the (A) MLS and (B) BEV method for each patient (y-axis) as a function of the number of the fraction compared with the reference (x-axis). The triangles stand for those patients where morphological changes where identified in the control CT, while the squares represent the patients that did not show changes.
For each patient, the average inter-fractional range difference Δ and average standard deviation ∑ obtained with the MLS method, together with the corresponding values Δ and ∑ for the BEV method.
| Patient | Δ |
| Δ |
|
|---|---|---|---|---|
| 002P | 0.2±1.0 | 2.3±0.3 | 0.3±0.9 | 1.9±0.3 |
| 003P | 1.2±0.7 | 2.4±0.3 | 0.1±1.0 | 2.4±0.3 |
| 004P | -1.0±0.7 | 2.9±0.3 | -0.6±0.9 | 2.7±0.5 |
| 005P | 1.0±1.1 | 2.0±0.4 | 0.3±1.4 | 1.8±0.4 |
| 008P | 2.0±0.8 | 2.6±0.5 | 1.5±0.6 | 2.6±0.5 |
| 009P | -0.6±0.9 | 3.0±0.2 | -0.1±0.8 | 2.4±0.2 |
| 006P | 1.2±0.6 | 3.7±0.5 | 1.6±1.1 | 3.4±0.4 |
| 007P | -0.8±1.1 | 5.8±0.4 | -2.6±1.8 | 4.8±0.3 |
Figure 7Coronal views of the control CT of patient 006P, with the (A) MLS outliers map O(x,y,z) and the (B) BEV outliers map O(x,y,z) superimposed, obtained by comparing fraction 17, fraction 25, and fraction 33 with the reference. The colored areas are the pencil beam paths that lead to anomalous range differences with respect to the reference, with red indicating a range overshoot with respect to the initial situation. The overshoot is especially pronounced in fraction 25 and 33. The colormaps were obtained as described in 2.5.1 and 2.5.2 for the MLS and the BEV method, respectively.
Figure 8Coronal views of the control CT of patient 007P, with superimposed the (A) MLS outliers map O(x,y,z) and (B) BEV outliers map O(x,y,z) , obtained by comparing fraction 14, fraction 17, and fraction 24 with the reference. The colored areas are the pencil beam paths that lead to anomalous range differences with respect to the reference, with red and blue indicating a range overshoot and undershoot with respect to the initial situation, respectively. Most clear are the beam undershoots (the blue areas). The colormaps were obtained as described in 2.5.1 and 2.5.2 for the MLS and the BEV method, respectively.